GlassScriptPhysician profile
Shahnaz Ahmed
NPI 1780681049
$6,528.22
in general payments reported to CMS, 2019-2025
43 companies · $755 in 2025
The $755 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $555 · 2021: $816 · 2022: $962 · 2023: $1,609 · 2024: $1,226 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,590.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $980.51 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $660.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $654.10 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $601.22 | 2019-2025 | |
| Abbvie INC. | $554.43 | 2021-2024 | Vraylar, Ubrelvy |
| Amgen INC. | $532.98 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $270.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $255.07 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.32 | 2021-2023 | |
| Abbott Laboratories | $188.10 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $142.55 | 2019-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.15 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $130.10 | 2019-2024 | Capvaxive |
| Astellas Pharma US INC | $110.28 | 2019-2022 | |
| Philips North America LLC | $108.08 | 2023-2025 | (Ck7) Extended Holter, Extended Holter, Event |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.98 | 2021-2024 | Xifaxan |
| Amarin Pharma, INC. | $80.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $76.19 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $73.12 | 2023 | Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $65.96 | 2022 | |
| Allergan, INC. | $60.74 | 2020 | |
| Shield Therapeutics INC | $54.95 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $44.86 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $41.98 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $41.27 | 2023 | Rexulti |
| Eisai INC. | $38.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.50 | 2024 | |
| Boston Scientific Corporation | $24.30 | 2023 | Watchman Access System |
| Abiomed | $24.24 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $23.98 | 2025 | Onpattro |
| Sumitomo Pharma America, INC. | $22.45 | 2024 | Gemtesa |
| Bausch Health US, LLC | $20.80 | 2022 | |
| Esperion Therapeutics, INC. | $20.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.06 | 2023 | Crysvita |
| Supernus Pharmaceuticals, INC. | $19.66 | 2021 | |
| Inari Medical, INC. | $17.19 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kyowa Kirin, INC. | $16.52 | 2023 | Crysvita |
| Lucid Diagnostics INC. | $16.17 | 2023 | |
| Almatica Pharma LLC | $14.86 | 2022 | |
| Medtronic, INC. | $14.46 | 2024 | Intellis Adaptivestim |
| Nevro Corp. | $13.64 | 2024 | Senza |
| Linus Health, INC. | $13.45 | 2024 | Core Cognitive Evaluation |
| Radius Health, INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahnaz Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.